Baidu
map

JAHA:左心房容积和功能与缺血性卒中长期发生率的关系

2022-09-10 MedSci原创 MedSci原创

经胸超声心动图测量的低LA排空分数与未来的缺血性卒中相关,且独立于房颤的发生。

缺血性卒中是世界范围内致残和死亡的主要原因。新出现的证据表明左心房(LA)结构、机械和电异常与缺血性卒中风险增加之间存在关联。一般人群的左房容积和排空分数可能涉及心房心肌病的结构和功能,在没有房颤或卒中的情况下,其与缺血性卒中的长期风险相关。

近日,心血管疾病领域权威杂志JAHA上发表了一篇研究文章,研究人员探究了LA体积和功能与缺血性卒中之间的关系。

在一个社区队列中,研究人员通过经胸超声心动图测量了左心房最小容积、左心房最大容积和左心房排空分数。该研究的主要终点为缺血性卒中。研究人员排除了已知房颤或既往缺血性卒中的参与者。

研究人员共纳入了1866名参与者。平均年龄为58±16岁,57%为女性。在中位随访16.5年(四分位数范围为11.4-16.8年)期间,共发生176例(9.4%)缺血性卒中。在以死亡为竞争风险的多变量原因特定回归模型和竞争风险模型中,LA排空分数与缺血性卒中相关(每减少10%的风险比[HR]为1.14[95%CI为1.02-1.28])和(亚分布HR为1.14[95%CI为1.01-1.29])。当对随访期间发生房颤的参与者进行调整时,这种相关性仍然存在(每降低10%的HR为1.12[95%CI为1.00-1.26])。在相同的模型中,LA体积与缺血性卒中无关。LA排空分数和LA体积与全因死亡率无关。

由此可见,经胸超声心动图测量的低LA排空分数与未来的缺血性卒中相关,且独立于房颤的发生。

原始出处:

Bjørn Strøier Larsen.et al.Left Atrial Volumes and Function, and Long‐Term Incidence of Ischemic Stroke in the General Population.JAHA.2022.https://www.ahajournals.org/doi/10.1161/JAHA.122.027031

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1893551, encodeId=e9fc189355155, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=126, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Mon Jul 03 12:53:10 CST 2023, time=2023-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1826820, encodeId=ded2182682037, content=<a href='/topic/show?id=e5283e89970' target=_blank style='color:#2F92EE;'>#发生率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=150, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37899, encryptionId=e5283e89970, topicName=发生率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Fri Apr 21 09:53:10 CST 2023, time=2023-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1659731, encodeId=9ba61659e31a4, content=<a href='/topic/show?id=da5c480e024' target=_blank style='color:#2F92EE;'>#左心房#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48070, encryptionId=da5c480e024, topicName=左心房)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=50dc25016902, createdName=ylz8411, createdTime=Wed Feb 01 14:53:10 CST 2023, time=2023-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1806547, encodeId=5410180654ec9, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Fri Jan 27 23:53:10 CST 2023, time=2023-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1268898, encodeId=b51612688981e, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Sun Sep 11 14:53:10 CST 2022, time=2022-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1627001, encodeId=6eca162e001bc, content=<a href='/topic/show?id=986a5101e46' target=_blank style='color:#2F92EE;'>#心房#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51017, encryptionId=986a5101e46, topicName=心房)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=20ba21064884, createdName=sodoo, createdTime=Sun Sep 11 14:53:10 CST 2022, time=2022-09-11, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1893551, encodeId=e9fc189355155, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=126, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Mon Jul 03 12:53:10 CST 2023, time=2023-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1826820, encodeId=ded2182682037, content=<a href='/topic/show?id=e5283e89970' target=_blank style='color:#2F92EE;'>#发生率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=150, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37899, encryptionId=e5283e89970, topicName=发生率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Fri Apr 21 09:53:10 CST 2023, time=2023-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1659731, encodeId=9ba61659e31a4, content=<a href='/topic/show?id=da5c480e024' target=_blank style='color:#2F92EE;'>#左心房#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48070, encryptionId=da5c480e024, topicName=左心房)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=50dc25016902, createdName=ylz8411, createdTime=Wed Feb 01 14:53:10 CST 2023, time=2023-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1806547, encodeId=5410180654ec9, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Fri Jan 27 23:53:10 CST 2023, time=2023-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1268898, encodeId=b51612688981e, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Sun Sep 11 14:53:10 CST 2022, time=2022-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1627001, encodeId=6eca162e001bc, content=<a href='/topic/show?id=986a5101e46' target=_blank style='color:#2F92EE;'>#心房#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51017, encryptionId=986a5101e46, topicName=心房)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=20ba21064884, createdName=sodoo, createdTime=Sun Sep 11 14:53:10 CST 2022, time=2022-09-11, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1893551, encodeId=e9fc189355155, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=126, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Mon Jul 03 12:53:10 CST 2023, time=2023-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1826820, encodeId=ded2182682037, content=<a href='/topic/show?id=e5283e89970' target=_blank style='color:#2F92EE;'>#发生率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=150, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37899, encryptionId=e5283e89970, topicName=发生率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Fri Apr 21 09:53:10 CST 2023, time=2023-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1659731, encodeId=9ba61659e31a4, content=<a href='/topic/show?id=da5c480e024' target=_blank style='color:#2F92EE;'>#左心房#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48070, encryptionId=da5c480e024, topicName=左心房)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=50dc25016902, createdName=ylz8411, createdTime=Wed Feb 01 14:53:10 CST 2023, time=2023-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1806547, encodeId=5410180654ec9, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Fri Jan 27 23:53:10 CST 2023, time=2023-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1268898, encodeId=b51612688981e, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Sun Sep 11 14:53:10 CST 2022, time=2022-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1627001, encodeId=6eca162e001bc, content=<a href='/topic/show?id=986a5101e46' target=_blank style='color:#2F92EE;'>#心房#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51017, encryptionId=986a5101e46, topicName=心房)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=20ba21064884, createdName=sodoo, createdTime=Sun Sep 11 14:53:10 CST 2022, time=2022-09-11, status=1, ipAttribution=)]
    2023-02-01 ylz8411
  4. [GetPortalCommentsPageByObjectIdResponse(id=1893551, encodeId=e9fc189355155, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=126, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Mon Jul 03 12:53:10 CST 2023, time=2023-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1826820, encodeId=ded2182682037, content=<a href='/topic/show?id=e5283e89970' target=_blank style='color:#2F92EE;'>#发生率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=150, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37899, encryptionId=e5283e89970, topicName=发生率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Fri Apr 21 09:53:10 CST 2023, time=2023-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1659731, encodeId=9ba61659e31a4, content=<a href='/topic/show?id=da5c480e024' target=_blank style='color:#2F92EE;'>#左心房#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48070, encryptionId=da5c480e024, topicName=左心房)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=50dc25016902, createdName=ylz8411, createdTime=Wed Feb 01 14:53:10 CST 2023, time=2023-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1806547, encodeId=5410180654ec9, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Fri Jan 27 23:53:10 CST 2023, time=2023-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1268898, encodeId=b51612688981e, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Sun Sep 11 14:53:10 CST 2022, time=2022-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1627001, encodeId=6eca162e001bc, content=<a href='/topic/show?id=986a5101e46' target=_blank style='color:#2F92EE;'>#心房#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51017, encryptionId=986a5101e46, topicName=心房)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=20ba21064884, createdName=sodoo, createdTime=Sun Sep 11 14:53:10 CST 2022, time=2022-09-11, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1893551, encodeId=e9fc189355155, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=126, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Mon Jul 03 12:53:10 CST 2023, time=2023-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1826820, encodeId=ded2182682037, content=<a href='/topic/show?id=e5283e89970' target=_blank style='color:#2F92EE;'>#发生率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=150, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37899, encryptionId=e5283e89970, topicName=发生率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Fri Apr 21 09:53:10 CST 2023, time=2023-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1659731, encodeId=9ba61659e31a4, content=<a href='/topic/show?id=da5c480e024' target=_blank style='color:#2F92EE;'>#左心房#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48070, encryptionId=da5c480e024, topicName=左心房)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=50dc25016902, createdName=ylz8411, createdTime=Wed Feb 01 14:53:10 CST 2023, time=2023-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1806547, encodeId=5410180654ec9, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Fri Jan 27 23:53:10 CST 2023, time=2023-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1268898, encodeId=b51612688981e, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Sun Sep 11 14:53:10 CST 2022, time=2022-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1627001, encodeId=6eca162e001bc, content=<a href='/topic/show?id=986a5101e46' target=_blank style='color:#2F92EE;'>#心房#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51017, encryptionId=986a5101e46, topicName=心房)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=20ba21064884, createdName=sodoo, createdTime=Sun Sep 11 14:53:10 CST 2022, time=2022-09-11, status=1, ipAttribution=)]
    2022-09-11 zhaohui6731
  6. [GetPortalCommentsPageByObjectIdResponse(id=1893551, encodeId=e9fc189355155, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=126, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Mon Jul 03 12:53:10 CST 2023, time=2023-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1826820, encodeId=ded2182682037, content=<a href='/topic/show?id=e5283e89970' target=_blank style='color:#2F92EE;'>#发生率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=150, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37899, encryptionId=e5283e89970, topicName=发生率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Fri Apr 21 09:53:10 CST 2023, time=2023-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1659731, encodeId=9ba61659e31a4, content=<a href='/topic/show?id=da5c480e024' target=_blank style='color:#2F92EE;'>#左心房#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48070, encryptionId=da5c480e024, topicName=左心房)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=50dc25016902, createdName=ylz8411, createdTime=Wed Feb 01 14:53:10 CST 2023, time=2023-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1806547, encodeId=5410180654ec9, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Fri Jan 27 23:53:10 CST 2023, time=2023-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1268898, encodeId=b51612688981e, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Sun Sep 11 14:53:10 CST 2022, time=2022-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1627001, encodeId=6eca162e001bc, content=<a href='/topic/show?id=986a5101e46' target=_blank style='color:#2F92EE;'>#心房#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51017, encryptionId=986a5101e46, topicName=心房)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=20ba21064884, createdName=sodoo, createdTime=Sun Sep 11 14:53:10 CST 2022, time=2022-09-11, status=1, ipAttribution=)]
    2022-09-11 sodoo

相关资讯

Neurology:吉训明院士团队发现常压高氧联合血管内治疗急性缺血性卒中患者的疗效

近期,由吉训明院士领衔的团队发表在Neurology上的研究探讨了常压高氧(NBO)联合血管内治疗(EVT)对急性缺血性卒中(AIS)患者的安全性和有效性。

Stroke:八年的抑郁症状轨迹和中风风险的关系

以多个时间点的高症状为特征的抑郁症状轨迹与卒中风险增加有关。

Circulation:新型抗凝剂可预防复发性缺血性卒中(PACIFIC-Stroke研究)

房颤是最常见的持续性心律失常,影响全世界3300多万人,与死亡、中风和其他血栓栓塞事件的发生率增加有关。心房颤动患者由于易形成心房血栓,中风的风险增加。由于直接口服抗凝剂(direct-acting

ESC 2022:Milvexian能减少缺血性卒中风险,且不增加出血风险(AXIOMATIC-SSP研究)

Milvexian是一种潜在的首创(first-in-class)口服因子XIa(FXIa)抑制剂(抗血栓),用于预防和治疗主要血栓性疾病。

JAMA Neuro:年轻人与老年人的脑卒中发病率的不同时间趋势

在高收入国家,卒中发病率的时间趋势因年龄而异

诊疗指南:缺血性卒中急性期治疗方法及并发症防治

缺血性卒中后焦虑、抑郁、认知功能下降严重影响患者预后,应尽早评估,积极干预。

Baidu
map
Baidu
map
Baidu
map